Medwave, Inc. (Nasdaq: MDWV), the innovator in sensor-based, non-invasive blood-pressure measuring solutions, announced today that Vision Source, the nation's premier network of independent doctors of optometry, has entered into a purchasing agreement for Medwave's Primo(TM) spot blood pressure monitoring product.
Representing the first major innovation to cuff- and mercury-based blood pressure measurement in more than 100 years, Primo has gained rapid acceptance among medical professionals and their patients due to its unique combination of speed, accuracy, flexibility and comfort.
With more than 1,450 eye care centers (more than 2,700 doctors) in all 50 states, Vision Source facilities are known for their personal attention, quality care and breakthrough technology. After evaluating Primo as a way to obtain effective, accurate and comfortable blood pressure readings for its patients, Vision Source observed that Primo accurately monitored even some of the most challenging patient types -- both large and small. Vision Source patients also appreciated the fact that Primo obtained an accurate blood pressure reading in only 12 seconds -- and without the discomfort of cuff-based devices.
"Vision Source is an innovative organization, and earning their trust and faith in Primo is a great compliment," said Tim O'Malley, Medwave, Inc. President and CEO. "Primo offers many advantages over conventional, cuff-based blood pressure products, and we're thrilled that Vision Source patients can now experience the difference. We are honored to add Vision Source to our growing list of Primo users, and we look forward to introducing all 1,450+ facilities to Primo."
About Vision Source
Vision Source is the nation's number one network of independent optometrists with more than 2,700 doctors in over 1,450 practices across the United States. With the combined buying power of a nationwide network, Vision Source doctors are better able to control their materials costs and offer their patients excellent value. Above all, each Vision Source practice is dedicated to maintaining the special relationship between a patient and his or her family eye doctor to ensure the best possible vision- and eye-health care. For more information, visit http://www.visionsource.com .
About Medwave
Medwave, Inc. develops, manufactures and distributes sensor-based non-invasive blood pressure solutions. Medwave's suite of products is designed for use in hospitals, clinics, doctor's offices and almost anywhere blood pressure monitoring occurs. Medwave has the required technology clearances to market its technology in the United States, Europe and Asia. Medwave's technology is installed in more than 500 hospitals and clinics worldwide. Medwave trades on the NASDAQ small cap market under the symbol MDWV. For more information, visit http://www.medwave.com .
Statements made in this release that are stated as expectations, plans, anticipations, prospects or future estimates or which otherwise look forward in time are considered "forward-looking statements" and involve a variety of risks and uncertainties, known and unknown, which are likely to affect the actual results. The following factors, among others, as well as factors discussed in Medwave's filings with the SEC, have affected and, in the future, could affect Medwave's actual results: resistance to the acceptance of new medical products, the market acceptance of the Primo(TM) system, the Vasotrac(R) system and other products of Medwave, hospital budgeting cycles, the possibility of adverse or negative results or commentary from clinical researchers or other users or evaluators of Medwave's products, Medwave's success in creating effective distribution channels for its products, Medwave's ability to scale up its manufacturing process, and delays in product development or enhancement or regulatory approval. Consequently, no forward- looking statement can be guaranteed and actual results may vary materially. Medwave(R), Vasotrac(R), Legato(TM), Primo(TM), and Fusion(TM) are trademarks of Medwave, Inc.